Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7118MR)

This product GTTS-WQ7118MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7118MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ41MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ8235MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ9368MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ13286MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ401MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ12739MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ15671MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ10168MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW